In partnership with
December 9, 2025
Built by a former cannabis regulator, Policy, Decoded helps operators read the policy terrain before it shifts beneath their feet.
Today’s edition stays with New York’s leadership shakeup, hemp rules that are finally landing on actual shops, and a run of numbers on sales, taxes, and pain meds that say more about the future than any one headline.
We work from the policy side of the table, but every briefing you read here rests on journalists who sat through hearings, pulled records, and knocked on doors to report these stories in the first place; they earn the bylines and deserve the support.
Today’s edition is supported by Fisher Investments and You.com. If you want your work in front of the same decision-makers, reply to this email and we will talk about sponsoring a future edition.
🏛️ New York’s search for a coherent cannabis map
🥤 Hemp bans colliding with local businesses
📈 Markets, taxes, and medical data
Steady hands in choppy waters.
7 Ways to Take Control of Your Legacy
Planning your estate might not sound like the most exciting thing on your to-do list, but trust us, it’s worth it. And with The Investor’s Guide to Estate Planning, preparing isn’t as daunting as it may seem.
Inside, you’ll find {straightforward advice} on tackling key documents to clearly spell out your wishes.
Plus, there’s help for having those all-important family conversations about your financial legacy to make sure everyone’s on the same page (and avoid negative future surprises).
Why leave things to chance when you can take control? Explore ways to start, review or refine your estate plan today with The Investor’s Guide to Estate Planning.
Start here — the day’s most important development, decoded for impact.
📌 What Happened: New York’s Office of Cannabis Management is in another leadership transition as acting executive director Felicia Reid departs, Chief Administrative Officer Susan Filburn steps in on an interim basis, and Deputy Counsel James Rogers also exits. A recent New York Times investigation into OCM’s handling of Omnium, from licensing through a contested recall, has amplified questions about how the agency sequences enforcement against well-capitalized operators while unlicensed shops continue to operate in full view. At the same time, regulators are highlighting new state data that tie participation in the medical cannabis program to lower opioid use, and they are using that signal to defend the medical framework as a public health asset. Growers and retailers are preparing to launch Metrc, working through trainings, data migration, and integrations on a tight calendar in a market that is already complicated. All of this is playing out in a state with more demand, more population, and more long-term upside than almost anywhere else in the country.
💡 Why It Matters: New York is building one of the most valuable cannabis markets in the world and doing it while everyone is watching for the stitch that comes loose. Every leadership change slows the small, boring work that makes a system feel predictable, like clear licensing calendars, standard responses to common problems, and enforcement priorities that stay the same from one news cycle to the next. The opioid findings give the state a rare piece of clean evidence that cannabis can sit inside mainstream health strategy instead of living in a separate lane reserved for people who already believe. A well handled seed-to-sale rollout can turn Metrc into something more useful than a compliance chore, because movement data can show where product actually goes and help distinguish sloppy operators from true bad actors. If those pieces come together, lawmakers and city officials will have a much easier time defending the project and investing political capital in it. If they drift or collide, the story hardens around the idea that New York wrote a big cannabis law and then never quite figured out how to run the thing.
🧠 THC Group Take: You can feel what this system needs when you talk to people from Buffalo, Syracuse, the Hudson Valley, and Queens in the same week. They want someone to say, out loud, what New York’s cannabis market should look like three years from now and then start building backwards from that picture. A serious map would spell out how many unlicensed storefronts the city intends to close or migrate into the legal market, which agencies own each part of that job, and how Metrc data, local inspectors, and community boards fit together instead of bumping into one another. It would stabilize the licensing pipeline so cultivators and retailers can plan capital and hiring on a real calendar, not on rumor and court dockets. It would also give the medical program a defined role in pain management and chronic care, so doctors and health systems know where cannabis fits and patients are not guessing. New York has the money, the people, and the political talent for that kind of work; what it has been missing is a leadership team that wakes up every morning thinking about the whole chess board rather than the latest fire.
Fast-moving headlines, flagged for what matters.
Hemp retailers and manufacturers across Louisiana are warning that Congress’s new hemp-derived THC ban could wipe out the drinks, vapes, and gummies that built their business model under the 2018 Farm Bill. Store owners in Acadiana describe the shutdown timeline as a “kick in the face,” since the federal change arrives after they invested in leases, payroll, and inventory under rules the state told them to follow. Trade advocates are already moving from shock to strategy, talking publicly about lost jobs while quietly sorting out whether the real fight lives in litigation, lobbying, or a push to narrow the law. The politics are tricky, because federal law now points one way while Louisiana’s own licensing and tax system still says these products belong on shelves. How hard these businesses and their allies lean on the state’s congressional delegation will tell you whether this becomes a narrow plea for delay or a broader effort to rewrite a ban that showed up long after the buildout. (The Advocate)
Chicago hemp beverage makers and shop owners are lining up against a proposed citywide ban on intoxicating hemp products, warning alderpeople that the ordinance would wipe out local jobs and hand the market to licensed cannabis dispensaries and illicit sellers. The measure, led by Ald. Marty Quinn, would ban most hemp-derived drinks, gummies, and vapes outside dispensaries within days of council approval, even as a federal hemp THC ban looms in 2026. Small manufacturers and retailers are pressing for age limits, product testing, and packaging rules instead, arguing that prohibition will only push consumers toward gas station synthetics and unregulated channels that already skirt every norm. With Mayor Brandon Johnson on record opposing a blanket ban and favoring regulation, the fight over this ordinance doubles as a test of how the city wants to balance child safety, tax revenue, and who gets to stay in the game while Washington rewrites the rules. (WTTW)
Wyoming hemp vendors are staring at an industry-wide crisis after the 10th Circuit upheld the state’s ban on “psychoactive” hemp products and Congress followed with a federal clampdown on hemp-derived THC. Retailers who lost their lawsuit over Senate Enrolled Act 24 now face a state definition of hemp that sweeps in total THC and synthetic cannabinoids, alongside a federal law that will soon treat much of their remaining product line as contraband. Many built out stores, processing labs, and distribution around the 2018 Farm Bill and Wyoming’s earlier rules, only to see the goalposts moved twice in quick succession. As one Casper shop prepares to close at the end of 2025, the message from the courts is blunt: states can tighten hemp rules even if compliant products remain legal on paper under federal law. (Torrington Telegram)
A Michigan judge has cleared the way for the state’s new 24 percent wholesale cannabis tax to take effect on January 1, rejecting arguments that the levy violated constitutional limits on how such revenue can be used. The tax applies to transfers from growers and processors into the adult-use supply chain and sits on top of the existing 10 percent excise tax, which turns every upstream price increase into a downstream squeeze for retailers and consumers. Lawmakers earmarked the new revenue for public safety, mental health, and school safety programs, which polls well but does nothing to fix pricing pressure in a market already defined by oversupply and eroding margins. Over the next year, the signal to watch is whether more operators quietly exit or consolidate rather than compete under a tax structure that treats them like a dependable cash machine. (Crain’s Detroit Business)
U.S. cannabis sales are pegged at about $38.4 billion for 2024, with forecasts climbing to roughly $115 billion by 2034 on an 11.6% compound annual growth rate and steady expansion of legal access. Analysts say marijuana products make up about 58% of current market share, while CBD dominates derivative sales at more than 60%, which reflects years of wellness branding that pulled CBD into mainstream retail faster than THC. Indoor cultivation shows up as the revenue leader with just over half the market, a reminder of how much capital is still locked in controlled-environment infrastructure even as energy costs and taxes eat margins. Recreational use accounts for most demand in this model and is projected to grow fastest, which assumes continued state-level legalization and no federal policy shock strong enough to knock consumers off their current path. The numbers read like optimism with footnotes, framing a large, growing pie that still sits on top of 280E, a hemp crackdown, and a financing environment that makes the underlying capex harder to support. (Market.us)
New Hampshire lawmakers are already filing 2026 cannabis bills, including a constitutional amendment that would give adults 21 and older a right to possess modest amounts for personal use and put that question on next November’s ballot. Because it is an amendment, the measure needs three-fifths support in both chambers but never reaches the governor’s desk, which lowers the political cost for Republicans who want legalization to advance without an open veto fight. The proposal arrives after years of House-passed legalization plans died in the Senate or collapsed in conference, including a high-profile attempt to run sales through a Liquor Commission franchise model. The ballot route is a rare outlet in a state without citizen initiatives and would still demand a two-thirds supermajority from voters, a high bar for the region’s last prohibition state. If it moves, the campaign will play out under a governor who opposes legalization and a Legislature that has struggled to agree on even bare-bones possession reforms. (Marijuana Moment)
Gov. Andy Beshear says Kentucky’s first medical marijuana dispensary should have product on shelves “within the next couple of weeks,” likely at The Post Dispensary in Ohio County, which has already cleared key inspections. The state has approved 80 business licenses so far, including 48 dispensaries and 16 cultivators, and nearly 24,000 residents have e-certifications tied mostly to chronic pain, PTSD, cancer, nausea, and seizure disorders. That patient base gives early operators a ready-made queue, although supply, pricing, and product mix will determine how quickly the program feels real outside the first few counties. For a state that built one of the tighter medical frameworks and dragged its feet for years, the launch will be judged less on ribbon cuttings and more on whether patients in rural regions can avoid long drives, high prices, and empty shelves in the first year. (Lexington Times)
New York’s Office of Cannabis Management is highlighting new state data showing that patients enrolled in the medical cannabis program use fewer opioids than similar patients who are not in the program. The findings draw on prescription monitoring information and suggest that medical cannabis access correlates with reductions in both the number and dosage of opioid prescriptions for chronic pain and related conditions. Regulators are framing the results as a public health win and a justification for keeping the medical program intact while adult-use sales slowly scale. Now lawmakers and health systems have to decide whether to treat this as an opportunity to integrate cannabis more formally into pain management protocols or keep it parked on the policy margins while overdose numbers remain stubbornly high. (Cannabis Business Times)
New Brunswick is weighing whether cannabis beverages should sit on restaurant menus and in provincial liquor stores, and not everyone in the public health world is happy about it. A local professor is urging caution, arguing that mixing alcohol and THC in the same service environment complicates training, liability, and youth exposure in ways the province has not really mapped. That kind of scrutiny is useful, although it often looks at risk in isolation instead of alongside what already happens in living rooms, parking lots, and cross-border shopping carts. For ANBL and lawmakers, the question now is whether to keep cannabis drinks in a narrow retail lane or start designing a hospitality framework that reflects how people already consume, with rules to match. (TJ News)
Ontario’s Alcohol and Gaming Commission is rolling out “Youth Compliance Monitors,” hiring 16- to 18-year-olds to work with inspectors and attempt underage purchases of cannabis and alcohol. The program replaces earlier mystery shops that used 18-year-olds in cannabis stores even though the legal purchase age is 19, which dulled the edge of any failed test. Regulators describe the new approach as a straightforward public safety tool and a way to keep retailers honest, yet it also highlights how far the system will go to prove kids cannot buy by sending kids in to try. For licensed stores that already feel squeezed while illicit sellers face little day-to-day scrutiny, it is one more reminder that enforcement falls heaviest where the paperwork lives. (StratCann)
Zimbabwe’s agriculture minister is pitching the country as an ideal hub for year-round cannabis and hemp cultivation, pointing to fertile soils, strong sunlight, and diverse microclimates that let farms stack greenhouse and open-field production on the same site. One flagship operation in Matabeleland North now runs two hectares of greenhouse cannabis and five hectares outdoors, exporting flower and hemp into Europe, the United States, and Asia while aligning itself with Harare’s value-add and rural transformation agenda. Officials talk about cannabis and hemp as part of a broader industrial crops push, with new institutions and a Hemp and Cannabis Industrial Working Group meant to pull research, licensing, and farmer support into a more coherent system. The opportunity sits in a familiar bind: global buyers want consistent, tested product and local leaders want export dollars fast, which raises uncomfortable questions about smallholder inclusion, environmental standards, and how much of the “green gold” actually stays in Zimbabwean hands. (MMJDaily / The Herald (Zimbabwe))
AI is all the rage, but are you using it to your advantage?
Successful AI transformation starts with deeply understanding your organization’s most critical use cases. We recommend this practical guide from You.com that walks through a proven framework to identify, prioritize, and document high-value AI opportunities. Learn more with this AI Use Case Discovery Guide.
From the hearing room to the comment section — we’re watching it all.
💰 Trulieve cleared its remaining 8% senior secured notes due 2026, retiring about $368 million in high-cost debt and buying itself more time on the federal reform clock. That kind of liability management is becoming the quiet playbook for large operators who lack normal refinancing options while cannabis remains inside federal drug law. (Cannabis Business Times)
🎁 A 25-item cannabis gift guide that runs from infused hot chocolate and THC “spirits” to designer glass and “I’m High Right Now” merch reads like any other lifestyle list, which is the point. Once cannabis gifts share page space with candles and barware, it becomes harder for prohibition politics to claim this category belongs in the shadows. Need a last minute gift idea? How about a free subscription to Policy, Decoded? GreenState
📑 A new Tax Court decision in Savage v. Commissioner closes off another tax angle for cannabis businesses by holding that W-2 wages disallowed under Section 280E cannot count toward the wage base for the Section 199A qualified business income deduction. The ruling turns 199A into a mirage for many operators who thought they could at least salvage a sliver of that 20 percent deduction, and it reinforces how 280E now ripples through newer parts of the tax code, not just the classic deduction lines. (EisnerAmper)
📊 cbdMD just cleared a NYSE American compliance warning, keeping its CBD brand on a national exchange at a time when many cannabis and hemp names have slipped to the OTC sheets or gone private. The reprieve buys management time to show there is still a standalone public story in CBD after years of pricing pressure and regulatory drift. Barron’s